Alan Warrander

Incanthera Plc operates as a holding company, which focuses on drug discovery and development of targeted medicines for the treatment of cancer. The firm products include Sol, EP0015, Equin & Duo-C. The company was founded on March 2, 2010 and is headquartered in Manchester, the United Kingdom.

Objective Capital Ltd. provides investment research. The company is based in London, UK. The British company was founded by Gabriel Didham.

Incanthera Research & Development Ltd. develops drug delivery solutions for solid tumor chemotherapy. It offers cancer therapies, such as ICT01-2588, a vascular disrupting agent and drug delivery platform for lung and prostate cancer; and ICT03-Es5, a bioreductive anticancer agent for lung, liver, and breast cancer. The company was founded by Alan McGowan, Paul Loadman, Laurence Patterson, Andrew John Michael Duley, John Anthony Hadfield, Robert Falconer, and Jason Gill in 2010 and is headquartered in Manchester, the United Kingdom.